ArticleCancer research communications2022

Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition.

Jingwei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.